Present and future challanges in the treatment of haemophilia: A clinician's perspective

Blood Transfusion

Volumn 11, Issue SUPPL. 4, 2013, Pages

  Mannucci, Pier Mannuccio ^a   Franchini, Massimo ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

Factor IX; Factor VIII; Haemophilia; Inhibitors; Recombinant technology

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

BLOOD COMPONENT THERAPY; CLINICAL PRACTICE; DRUG INDICATION; DRUG INFORMATION; DRUG RESEARCH; HEMOPHILIA A; HEMOPHILIA B; HUMAN; REVIEW;

DRUG THERAPY; HEMOPHILIA A; HUMANS;

EID: 84885642596     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.012s     Document Type: Review

References (37)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9. (Pubitemid 32497033)
2. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447-56.
3. White GC, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560. (Pubitemid 32233035)
4. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44. (Pubitemid 47236278)
5. Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
6. Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus 2013; 11: 178-82.
7. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24.
8. Nilsson IM. Experience with prophylaxis in Sweden. Semin Hematol 1993; 30: 16-9. (Pubitemid 23212311)
9. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90: 2515-21. (Pubitemid 27413458)
10. Pipe SW. Recombinant clotting factors. Thromb Haemost 2008; 99: 840-50. (Pubitemid 351705300)
11. Astermark J, Donfield SM, DiMichele DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA Novo Seven Comparative (FENOC) Study. Blood 2007; 109: 546-51. (Pubitemid 46105952)
12. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010; 16: 66-70.
13. Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
14. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010; 148: 522-33.
15. Plug I, Van Der Bom JG, Peters M, et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006; 4: 510-6.
16. Tagliaferri A, Franchini M, Coppola A, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
17. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35. (Pubitemid 36874391)
18. Fuchs B, Fisseau C, Trawnicek L, et al. von Willebrand factor function under physiological flow conditons. Comparison of five VWF-containing concentrates in an in vitro flowchamber model. XXII Intenational Society of Thrombosis and Haemostasis (ISTH) Congress. 11-16 July 2009, Boston, MA, USA. Abs PP-WE-624.
19. Hironaka T, Furukawa K, Esmon PC, et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 1992; 267: 8012-20.
20. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256-65.
21. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia. 2007; 13 (Suppl 5): 65-8. (Pubitemid 350253407)
22. Gouw SC, Van Der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
23. Kessler CM, Iorio A. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia 2013; 19: 351-4.
24. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48.
25. Rubinger M, Lillicrap D, Rivard GE, et al. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia 2008; 14: 281-6. (Pubitemid 351338688)
26. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A metaanalysis of prospective clinical studies. J Thromb Haemost 2011; 9: 2180-92.
27. Iorio A, Marcucci M, Makris M. Concentrate-related inhibitor risk: is a difference always real? J Thromb Haemost 2011; 9: 2176-9.
28. Lillicrap D. Improvements in factor concentrates. Curr Opin Hematol 2010; 17: 393-7.
29. Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87 (Suppl 1): S33-9.
30. Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood 2012; 119: 4108-14.
31. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013; 11 (Suppl 1): 84-98
32. Tiede A, Brand B, Fischer R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: firstin-human trial of glyco PEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670-8.
33. Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
34. Shapiro AD, Ragni MV, Valentino LA, et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72.
35. Powell JS, Josephson NC, Quon D, et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7.
36. Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.
37. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 36525: 2357-65.